Gender discrepancies in bladder cancer: potential explanations

References

• Najari BB, Rink M, Li PS, et al. Sex disparities in cancer mortality: the risks of being a man in the United States. J Urol. 2013;189(4):1470–1474.
   PubMed Web of Science ®Google Scholar
• Mungan NA, Aben KK, Schoenberg MP, et al. Gender differences in stage-adjusted bladder cancer survival. Urology. 2000;55(6):876–880.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E86.
   PubMed Web of Science ®Google Scholar
• Ebrahimi H, Amini E, Pishgar F, et al. Global, regional and national burden of bladder cancer, 1990 to 2016: results from the GBD study 2016. J Urol. 2019;201(5):893–901.
   PubMed Web of Science ®Google Scholar
• Moe A, Hayne D Bladder cancer: a cancer in crisis. MJA Insight+ [Internet]; 2019. Available from: https://insightplus.mja.com.au/2019/20/bladder-cancer-a-cancer-in-crisis/. p. 20.
   Google Scholar
• Australian Institute of Health & Welfare. Cancer data in Australia. Canberra: AIHW; 2019.
   Google Scholar
• Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27(3):295–300.
   PubMed Web of Science ®Google Scholar
• Svatek RS, Hollenbeck BK, Holmäng S, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014;66(2):253–262.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Babjuk M, Bellmunt J, et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort(dagger): under the auspices of the EAU-ESMO guidelines committees. Eur Urol. 2020;77(2):223–250.
   PubMed Web of Science ®Google Scholar
• McCombie S, Hayne D. Current trends in bladder cancer in Australia. Trends Urol Men’s Health. 2014;5(3):16–20.
   Google Scholar
• Dobruch J, Daneshmand S, Fisch M, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016;69(2):300–310.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Sfakianos JP, Droller MJ, et al. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 2010;105(3):300–308.
   PubMed Web of Science ®Google Scholar
• Andreassen BK, Grimsrud TK, Haug ES. Bladder cancer survival: women better off in the long run. Eur J Cancer. 2018;95:52–58.
   PubMed Web of Science ®Google Scholar
• Keck B, Ott OJ, Haberle L, et al. Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy. World J Urol. 2013;31(5):1023–1028.
   PubMed Web of Science ®Google Scholar
• Richters A, Dickman PW, Witjes JA, et al. Bladder cancer survival: women only fare worse in the first two years after diagnosis. Urol Oncol. 2019;37(12):853–861.
   PubMed Web of Science ®Google Scholar
• Mancini M, Righetto M, Baggio G. Spotlight on gender-specific disparities in bladder cancer. Urologia.  2020;87(3): 103–114.
   Web of Science ®Google Scholar
• Puente D, Malats N, Cecchini L, et al. Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer. Eur Urol. 2003;43(1):53–62.
   PubMed Web of Science ®Google Scholar
• Radkiewicz C, Edgren G, Johansson ALV, et al. Sex differences in urothelial bladder cancer survival. Clin Genitourin Cancer. 2020;18(1):26–34 e6.
   PubMed Web of Science ®Google Scholar
• Mungan NA, Kiemeney LA, van Dijck JA, et al. Gender differences in stage distribution of bladder cancer. Urology. 2000;55(3):368–371.
   PubMed Web of Science ®Google Scholar
• Marks P, Soave A, Shariat SF, et al. Female with bladder cancer: what and why is there a difference? Transl Androl Urol. 2016;5(5):668–682.
   PubMed Web of Science ®Google Scholar
• Scosyrev E, Noyes K, Feng C, et al. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer. 2009;115(1):68–74.
   PubMed Web of Science ®Google Scholar
• Datta GD, Neville B, Datta NS, et al. Gender disparities in bladder cancer survival: an assessment of socio-demographic factors. Washington, DC: AACR; 2006.
   Google Scholar
• Alanee S, Bauman J, Dynda D, et al. Conservative management and female gender are associated with increased cancer‐specific death in patients with isolated primary urothelial carcinoma in situ. Eur J Cancer Care (Engl). 2015;24(3):444–449.
   PubMed Web of Science ®Google Scholar
• Scosyrev E, Golijanin D, Wu G, et al. The burden of bladder cancer in men and women: analysis of the years of life lost. BJU Int. 2012;109(1):57–62.
   PubMed Web of Science ®Google Scholar
• Palou J, Sylvester RJ, Faba OR, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol. 2012;62(1):118–125.
   PubMed Web of Science ®Google Scholar
• Santos F, Dragomir A, Kassouf W, et al. Predictors of preoperative delays before radical cystectomy for bladder cancer in Q uebec, C anada: a population‐based study. BJU Int. 2015;115(3):389–396.
   PubMed Web of Science ®Google Scholar
• Martin-Doyle W, Leow JJ, Orsola A, et al. Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol. 2015;33(6):643–650.
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Zhu F, Herr HW. The effect of gender on response to bacillus Calmette‐Guérin therapy for patients with non‐muscle‐invasive urothelial carcinoma of the bladder. BJU Int. 2010;106(3):357–361.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Margulis V, Lotan Y, et al. Nomograms for bladder cancer. Eur Urol. 2008;54(1):41–53.
   PubMed Web of Science ®Google Scholar
• Kluth LA, Rieken M, Xylinas E, et al. Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. Eur Urol. 2014;66(5):913–919.
   PubMed Web of Science ®Google Scholar
• Messer JC, Shariat SF, Dinney CP, et al. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology. 2014;83(4):863–867.
   PubMed Web of Science ®Google Scholar
• Tilki D, Svatek RS, Karakiewicz PI, et al. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol. 2010;183(1):87–93.
   PubMed Web of Science ®Google Scholar
• Liberman D, Alasker A, Sun M, et al. Radical cystectomy for patients with pT4 urothelial carcinoma in a large population‐based study. BJU Int. 2011;107(6):905–911.
   PubMed Web of Science ®Google Scholar
• Soave A, Dahlem R, Hansen J, et al. Gender-specific outcomes of bladder cancer patients: a stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. Eur J Surg Oncol. 2015;41(3):368–377.
   PubMed Web of Science ®Google Scholar
• Mitra AP, Skinner EC, Schuckman AK, et al., editors. Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients. Urologic Oncology: Seminars and Original Investigations; 2014: Elsevier.
   Google Scholar
• Siegrist T, Savage C, Shabsigh A, et al., editors. Analysis of gender differences in early perioperative complications following radical cystectomy at a tertiary cancer center using a standardized reporting methodology. Urologic Oncology: Seminars and Original Investigations; 2010: Elsevier.
   Google Scholar
• Cardenas-Turanzas M, Cooksley C, Kamat AM, et al. Gender and age differences in blood utilization and length of stay in radical cystectomy: a population-based study. Int Urol Nephrol. 2008;40(4):893–899.
   PubMed Web of Science ®Google Scholar
• Kimura S, Iwata T, Abufaraj M, et al. Impact of gender on chemotherapeutic response and oncologic outcomes in patients treated with radical cystectomy and perioperative chemotherapy for bladder cancer: a systematic review and meta-analysis. Clin Genitourin Cancer. 2020;18(2):78–87.
   PubMed Web of Science ®Google Scholar
• McCombie SP, Bangash HK, Kuan M, et al. Delays in the diagnosis and initial treatment of bladder cancer in Western Australia. BJU Int. 2017;120(Suppl 3):28–34.
   PubMed Web of Science ®Google Scholar
• Hollenbeck BK, Dunn RL, Ye Z, et al. Delays in diagnosis and bladder cancer mortality. Cancer. 2010;116(22):5235–5242.
   PubMed Web of Science ®Google Scholar
• Wallace D, Bryan R, Dunn J, et al., Group WMUR. Delay and survival in bladder cancer. BJU Int. 2002;89(9):868–878.
   PubMed Web of Science ®Google Scholar
• Henning A, Wehrberger M, Madersbacher S, et al. Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer? BJU Int. 2013;112(1):68–73.
   PubMed Web of Science ®Google Scholar
• Vermeulen SH, Hanum N, Grotenhuis AJ, et al. Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study. Br J Cancer. 2015;112(3):594–600.
   PubMed Web of Science ®Google Scholar
• Kantor AF, Hartge P, Hoover RN, et al. Urinary tract infection and risk of bladder cancer. Am J Epidemiol. 1984;119(4):510–515.
   PubMed Web of Science ®Google Scholar
• Ngo B, Perera M, Papa N, et al. Factors affecting the timeliness and adequacy of haematuria assessment in bladder cancer: a systematic review. BJU Int. 2017;119(Suppl 5):10–18.
   PubMed Web of Science ®Google Scholar
• Garg T, Pinheiro LC, Atoria CL, et al. Gender disparities in hematuria evaluation and bladder cancer diagnosis: a population based analysis. J Urol. 2014;192(4):1072–1077.
   PubMed Web of Science ®Google Scholar
• Johnson EK, Daignault S, Zhang Y, et al. Patterns of hematuria referral to urologists: does a gender disparity exist? Urology. 2008;72(3):498–502.
   PubMed Web of Science ®Google Scholar
• Cohn JA, Vekhter B, Lyttle C, et al. Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims‐based investigation. Cancer. 2014;120(4):555–561.
   PubMed Web of Science ®Google Scholar
• Wu H, Wang X, Zhang L, et al. Association between N-acetyltransferase 2 polymorphism and bladder cancer risk: results from studies of the past decade and a meta-analysis. Clin Genitourin Cancer. 2016;14(2):122–129.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wu B, Zha Z, et al. Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):716.
   PubMed Web of Science ®Google Scholar
• Izumi K, Zheng Y, Hsu JW, et al. Androgen receptor signals regulate UDP‐glucuronosyltransferases in the urinary bladder: A potential mechanism of androgen‐induced bladder carcinogenesis. Mol Carcinog. 2013;52(2):94–102.
   PubMed Web of Science ®Google Scholar
• Kellen E, Hemelt M, Broberg K, et al. Pooled analysis and meta-analysis of the glutathione S-transferase P1 Ile 105Val polymorphism and bladder cancer: a HuGE-GSEC review. Am J Epidemiol. 2007;165(11):1221–1230.
   PubMed Web of Science ®Google Scholar
• McGrath M, Michaud DS, De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol. 2006;163(3):236–244.
   PubMed Web of Science ®Google Scholar
• Daugherty SE, Lacey JV Jr, Pfeiffer RM, et al. Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH‐AARP diet and health study. Int J Cancer. 2013;133(2):462–472.
   PubMed Web of Science ®Google Scholar
• Dietrich K, Demidenko E, Schned A, et al. Parity, early menopause and the incidence of bladder cancer in women: A case–control study and meta-analysis. Eur J Cancer. 2011;47(4):592–599.
   PubMed Web of Science ®Google Scholar
• Cantwell MM, Lacey JV Jr, Schairer C, et al. Reproductive factors, exogenous hormone use and bladder cancer risk in a prospective study. Int J Cancer. 2006;119(10):2398–2401.
   PubMed Web of Science ®Google Scholar
• Boorjian S, Ugras S, Mongan NP, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology. 2004;64(2):383–388.
   PubMed Web of Science ®Google Scholar
• Barocas DA, Kawamoto H, Dreizin DF, et al. Five-alpha-reductase expression in benign and malignant urothelium: correlation with disease characteristics and outcome. Urology. 2005;66(5):1134–1139.
   PubMed Web of Science ®Google Scholar
• Johnson AM, O’Connell MJ, Miyamoto H, et al. Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. BMC Urol. 2008;8(1):7.
   PubMedGoogle Scholar
• Miyamoto H, Yang Z, Chen Y-T, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99(7):558–568.
   PubMed Web of Science ®Google Scholar
• Mäkelä S, Strauss L, Kuiper G, et al. Differential expression of estrogen receptors α and β in adult rat accessory sex glands and lower urinary tract. Mol Cell Endocrinol. 2000;164(1–2):109–116.
   PubMed Web of Science ®Google Scholar
• Pelletier G. Invited Reviews-Localization of androgen and estrogen receptors in rat and primate tissues. Histol Histopathol. 2000;15(4):1261–1270.
   PubMed Web of Science ®Google Scholar
• Shen SS, Smith CL, Hsieh JT, et al. Expression of estrogen receptors‐α and‐β in bladder cancer cell lines and human bladder tumor tissue. Cancer: Interdiscip Int J Am Cancer Soc. 2006;106(12):2610–2616.
   Google Scholar
• George SK, Tovar-Sepulveda V, Shen SS, et al. Chemoprevention of BBN-induced bladder carcinogenesis by the selective estrogen receptor modulator tamoxifen. Transl Oncol. 2013;6(3):244.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Okuno N, Weiss H, et al. Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. Urology. 2007;69(6):1221–1226.
   PubMed Web of Science ®Google Scholar
• Hoffman KL, Lerner SP, Smith CL. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation. Hormones Cancer. 2013;4(1):24–35.
   PubMed Web of Science ®Google Scholar
• Gakis G, Stenzl A. Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity. World J Urol. 2013;31(5):1059–1064.
   PubMed Web of Science ®Google Scholar
• Maralani S, Wood DP Jr, Grignon D, et al. Incidence of urethral involvement in female bladder cancer: an anatomic pathologic study. Urology. 1997;50(4):537–541.
   PubMed Web of Science ®Google Scholar
• Saez S, Martin PM. Evidence of estrogen receptors in the trigone area of human urinary bladder. J steroid Biochem. 1981;15:317–320.
   PubMedGoogle Scholar
• Madeb R, Messing EM, editors. Gender, racial and age differences in bladder cancer incidence and mortality. Urologic Oncology: Seminars and Original Investigations; 2004: Elsevier.
   Google Scholar
• Schilling D, Horstmann M, Nagele U, et al. Cystectomy in women. BJU Int. 2008;102(9 Pt B):1289–1295.
   PubMed Web of Science ®Google Scholar
• Jiang X, Yuan J-M, Skipper PL, et al. Environmental tobacco smoke and bladder cancer risk in never smokers of Los Angeles county. Cancer Res. 2007;67(15):7540–7545.
   PubMed Web of Science ®Google Scholar
• Hemelt M, Yamamoto H, Cheng KK, et al. The effect of smoking on the male excess of bladder cancer: A meta‐analysis and geographical analyses. Int J Cancer. 2009;124(2):412–419.
   PubMed Web of Science ®Google Scholar
• Rink M, Xylinas E, Babjuk M, et al. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol. 2012;188(6):2120–2128.
   PubMed Web of Science ®Google Scholar
• Rink M, Zabor EC, Furberg H, et al. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. Eur Urol. 2013;64(3):456–464.
   PubMed Web of Science ®Google Scholar
• Castelao JE, Yuan J-M, Skipper PL, et al. Gender-and smoking-related bladder cancer risk. J Natl Cancer Inst. 2001;93(7):538–545.
   PubMed Web of Science ®Google Scholar
• Hayne D, Arya M, Quinn MJ, et al. *Current trends in bladder cancer in England and Wales. J Urol. 2004;172(3):1051–1055.
   PubMed Web of Science ®Google Scholar
• Koutros S, Silverman DT, Baris D, et al. Hair dye use and risk of bladder cancer in the New England bladder cancer study. Int J Cancer. 2011;129(12):2894–2904.
   PubMed Web of Science ®Google Scholar
• Li N, Yang L, Zhang Y, et al. Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis. 2011;204(2):217–223.
   PubMed Web of Science ®Google Scholar
• Konety BR, Joslyn SA. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol. 2003;170(5):1765–1771.
   PubMed Web of Science ®Google Scholar
• Schmid M, Rink M, Traumann M, et al. Evidence from the ‘PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)’study: how are preoperative patient characteristics associated with urinary diversion type after radical cystectomy for bladder cancer? Ann Surg Oncol. 2015;22(3):1032–1042.
   PubMed Web of Science ®Google Scholar
• Lavallée LT, Schramm D, Witiuk K, et al. Peri-operative morbidity associated with radical cystectomy in a multicenter database of community and academic hospitals. Plos One. 2014;9(10):e111281.
   PubMed Web of Science ®Google Scholar
• Australian Institure of Health & Welfare. Older Australia at a glance. Canberra: AIHW; 2018.
   Google Scholar
• Ooi WL, Lee F, Wallace DMA, et al. ‘One stop’haematuria clinic in Fremantle Hospital, Western Australia: a report of the first 500 patients. BJU Int. 2011;108:62–66.
   PubMed Web of Science ®Google Scholar
• Casey MF, Wisnivesky J, Le VH, et al. The relationship between centralization of care and geographic barriers to cystectomy for bladder cancer. Bladder Cancer. 2016;2(3):319–327.
   PubMed Web of Science ®Google Scholar